Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, Arbutus is developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that they intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Arbutus’ lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. Arbutus has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). Arbutus is also exploring oncology applications for its internal PD-L1 portfolio.
Arbutus has a very broad HBV product pipeline of assets to reduce surface antigen, suppress viral replication, and boost the immune system, which include: RNAi therapeutic, Capsid Inhibitor, oral PD-L1 inhibitor, oral HBV RNA Destabilizers and additional coronavirus pre-clinical assets.
June 25 2022
June 6 2022